VLA 0.00% $1.75 viralytics limited

Vienna Conference Looks Promising, page-11

  1. 528 Posts.
    lightbulb Created with Sketch. 36
    This second one may actually have some new data in it - the first will not (a previously reported animal study).

    They should now be at a stage they can provide somewhat final results regarding the measured viral and immune response during the CALM extension study.

    However the big news required remains immune response from the STORM study (intravenous). Off the back of that perhaps combined with some early info from human combo trials, we need to see partnering.
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.